Literature DB >> 1061119

Characterization of residual enzyme activity in fibroblasts from patients with adenosine deaminase deficiency and combined immunodeficiency: evidence for a mutant enzyme.

R Hirschhorn, N Beratis, F S Rosen.   

Abstract

A proportion of patients suffering from the autosomal recessive form of severe combined immunodeficiency have an inherited deficiency of adenosine deaminase (EC 3.5.4.4; adenosine aminohydrolase) (erythrocyte isoenzyme). We have, however, found residual adenosine deaminase activity in fibroblasts derived from four such patients. The enzyme responsible for this activity is biochemically homologous with the high-molecular-weight tissue isoenzyme of adenosine deaminase found in normal fibroblasts and tissues other than erythrocytes. The residual adenosine deaminase has an altered electrophoretic mobility, increased heat stability as compared to normals, and can be detected in fibroblasts of obligate heterozygotes. Our previous studies have indicated that the tissue and erythrocyte adenosine deaminase isoenzymes contain a common catalytic unit controlled by the gene affected in severe combined immunodeficiency with absent adenosine deaminase (erythrocyte isoenzyme). This residual adenosine deaminase therefore represents, most likely, a "mutant" enzyme in fibroblasts of patients with severe combined immunodeficiency. The data support the hypothesis that, in these patients, severe combined immunodeficiency is due to a mutation at the adenosine deaminase locus.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1061119      PMCID: PMC335871          DOI: 10.1073/pnas.73.1.213

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Workshop on severe combined immunological deficiency disease and adenosine deaminase deficiency. Albany, New York, on October 1, 1973.

Authors:  R J Pickering; B Pollara; H J Meuwissen
Journal:  Clin Immunol Immunopathol       Date:  1974-11

3.  Effect of cyclic 3',5'-adenosine monophosphate and theophylline on lymphocyte transformation.

Authors:  R Hirschhorn; J Grossman; G Weissmann
Journal:  Proc Soc Exp Biol Med       Date:  1970-04

4.  Alterations in isozymes of adenosine deaminase during stimulation of human peripheral blood lymphocytes.

Authors:  R Hirschhorn; V Levytska
Journal:  Cell Immunol       Date:  1974-06       Impact factor: 4.868

5.  Multiple forms of human adenosine deaminase. II. Isolation and properties of a conversion factor from human lung.

Authors:  H Nishihara; S Ishikawa; K Shinkai; H Akedo
Journal:  Biochim Biophys Acta       Date:  1973-04-12

6.  Evidence for control of several different tissue-specific isozymes of adenosine deaminase by a single genetic locus.

Authors:  R Hirschhorn; V Levytaka; B Pollara; H J Meuwissen
Journal:  Nat New Biol       Date:  1973-12-19

7.  Molecular form of adenosine deaminase in severe combined immunodeficiency.

Authors:  M B Van der Weyden; R H Buckley; W N Kelley
Journal:  Biochem Biophys Res Commun       Date:  1974-04-08       Impact factor: 3.575

8.  Detection of the carrier state in combined immunodeficiency disease associated with adenosine deaminase deficiency.

Authors:  C R Scott; S H Chen; E R Giblett
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

9.  Further data on the adenosine deaminase (ADA) polymprphism and a report of a new phenotype.

Authors:  D A Hopkinson; P J Cook; H Harris
Journal:  Ann Hum Genet       Date:  1969-05       Impact factor: 1.670

10.  Adenosine-deaminase deficiency in a child diagnosed prenatally.

Authors:  R Hirschhorn; N Beratis; F S Rosen; R Parkman; R Stern; S Polmar
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

View more
  19 in total

1.  Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency.

Authors:  W P Schrader; B Pollara; H J Meuwissen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

Review 2.  Combined immunodeficiency and inborn errors of purine metabolism.

Authors:  H J Meuwissen; B Pollara
Journal:  Blut       Date:  1978-10-13

3.  Demonstration of adenosine deaminase activity in human fibroblast lysosomes.

Authors:  E R Lindley; R L Pisoni
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

4.  A polyoma mutant that encodes small T antigen but not middle T antigen demonstrates uncoupling of cell surface and cytoskeletal changes associated with cell transformation.

Authors:  T J Liang; G G Carmichael; T L Benjamin
Journal:  Mol Cell Biol       Date:  1984-12       Impact factor: 4.272

Review 5.  The biochemical basis of immunodeficiency disease.

Authors:  K O Raivio
Journal:  Eur J Pediatr       Date:  1980-10       Impact factor: 3.183

6.  Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.

Authors:  P E Daddona; B S Mitchell; H J Meuwissen; B L Davidson; J M Wilson; C A Koller
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

Review 7.  Nucleotide-metabolizing enzymes and lymphocyte differentiation.

Authors:  R W Barton; I Goldschneider
Journal:  Mol Cell Biochem       Date:  1979-12-14       Impact factor: 3.396

8.  Assignment of adenosine deaminase complexing protein (ADCP) gene(s) to human chromosome 2 in rodent-human somatic cell hybrids.

Authors:  E Herbschleb-Voogt; K H Grzeschik; P L Pearson; P Meera Khan
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

Review 9.  Analysis of normal and mutant forms of human adenosine deaminase - a review.

Authors:  P E Daddona; W N Kelley
Journal:  Mol Cell Biochem       Date:  1980-02-08       Impact factor: 3.396

10.  Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is due to an aberration of the ADA protein.

Authors:  D Valerio; M G Duyvesteyn; H van Ormondt; P Meera Khan; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1984-01-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.